biotech / news / / The Tribune
AstraZeneca and Roche Diagnostics Asia Pacific announce a three-year Memorandum of Understanding.
AstraZeneca and Roche Diagnostics signed a first-in-region three-year MoU to advance digital pathology in Asia.
KEY POINTS
- AI-powered workflows can reclassify 24% of HER2-negative breast cancer cases as HER2-low, expanding therapy access.
- Only 17% of clinicians in Asia are very aware of advanced pathology technologies, revealing a major adoption gap.
- Roche received FDA Breakthrough Device designation for the first AI-powered TROP2 companion diagnostic for lung cancer.
- Educational initiatives will target nine Asia markets to accelerate AI-assisted pathology adoption in cancer care.
COMPANIES
Summarized by Newsio from The Tribune. How we summarize →